Clinical Trial Update: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports results from testing different dosing regimens of donanemab in adults with early Alzheimer's disease. Results were posted on 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Donanemab (LY3002813) (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease, Dementia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-14